WO2007029159A1 - A process for the preparation of lyophilized sodium bicarbonate - Google Patents
A process for the preparation of lyophilized sodium bicarbonate Download PDFInfo
- Publication number
- WO2007029159A1 WO2007029159A1 PCT/IB2006/053085 IB2006053085W WO2007029159A1 WO 2007029159 A1 WO2007029159 A1 WO 2007029159A1 IB 2006053085 W IB2006053085 W IB 2006053085W WO 2007029159 A1 WO2007029159 A1 WO 2007029159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium bicarbonate
- crystalline
- temperature
- preparation
- less
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D7/00—Carbonates of sodium, potassium or alkali metals in general
- C01D7/35—Varying the content of water of crystallisation or the specific gravity
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Definitions
- the present invention provides a process for the preparation of crystalline lyophilized sodium bicarbonate.
- Sodium bicarbonate is used as an inactive ingredient in injectable pharmaceutical preparations such as ertapenem, octreotide acetate, fomivirsen sodium, mannitol, and poractant alfa and in oral tablets such as ESTRATEST® (Esterified Estrogens and Methyltestosterone) and terfenadine.
- Sterile water for injection containing sodium bicarbonate is used for reconstituting certain drugs such as ceftizoxime, cefazolin, cimetidine hydrochloride, cefoxitin sodium and ceftriaxone sodium.
- Sodium bicarbonate is also used in the preparation of sodium salts of the drugs such as cilastatin and cefotetan.
- Sodium bicarbonate is also an ingredient in oral solutions for gastrointestinal lavage such as COLYTE ® . It is also used for pH neutralization of drugs such as metronidazole and ascorbic acid prior to parenteral administration.
- Sodium bicarbonate of higher purity is commercially produced by injecting gaseous carbon dioxide into a sodium carbonate solution of such composition that results in crystallization of sodium bicarbonate as the solution becomes fully saturated with carbon dioxide. The crystals are separated by centrifuging and filtering, and then dried to remove the traces of moisture.
- sodium bicarbonate wet cake is traditionally dried by using conventional rotary steam tube dryers. Such methods involve high temperature dehydration and steam pressure up to thirty five atmosphere.
- the dried material usually has high bulk density and the crystals resulting from this process usually have irregular particle size distribution and dendritic structures, which are physically weak and readily disintegrate into finer fragments on handling. Further, at higher temperatures, sodium bicarbonate tends to be converted into sodium carbonate.
- U.S. Patent No 3,647,365 describes a method to obtain hollow beads of sodium bicarbonate having bulk density of 25 - 32 pounds per cubic foot, and the process involves drying of the product by warming under carbon dioxide environment. Such methods of drying by warming consume considerable time for complete removal of the moisture.
- U.S. Patent No. 5,290,322 provides a method to prepare sodium bicarbonate crystals having regular particle size distribution by mobile bed crystallization method. However, the method needs to be carried out at a temperature of about 70 0 C under carbon dioxide environment and results in a mean particle size of about 900 microns.
- the present inventors have now surprisingly found that crystalline sodium bicarbonate with high purity; optimum bulk density and uniform particle size distribution can be prepared in comparatively a shorter reaction time by lyophilizing a solution of sodium bicarbonate.
- the method does not require carbon dioxide atmosphere, high pressure or temperature conditions, and yet results in a pure product with moisture content less than about 0.25 % w/w.
- the present method is suitable for industrial preparation of pharmaceutical grade crystalline sodium bicarbonate.
- a first aspect of the present invention provides a crystalline lyophilized sodium bicarbonate.
- the crystalline lyophilized sodium bicarbonate of the present invention has bulk density ranging from about 0.10 to about 0.25 g/ml and tapped density ranging from 0.30 to about 0.40 g/ml.
- a second aspect of the invention provides crystalline lyophilized sodium bicarbonate having particle size wherein 90% of the particles (do 9 ) have particle diameter 40 microns or less.
- a third aspect of the present invention provides a process for the preparation of crystalline sodium bicarbonate, wherein the process comprises a) lyophilizing the solution of sodium bicarbonate in lyophilizer having tray thickness of about 15 mm or less, and b) isolating crystalline sodium bicarbonate from the reaction mass thereof.
- Sodium bicarbonate of any morphology or particle size range prepared by any of the prior art methods can be used as a starting substrate.
- the sodium bicarbonate is dissolved in water at a temperature of about 5° to about 15°C.
- the solution is optionally filtered through a micron filter and transferred to lyophilizer trays having the temperature of about 0° to about -10 0 C.
- the thickness of the solution layer on the lyophilizer trays is less than about 15 millimeter.
- the solution is cooled to a temperature of -20 0 C or less under vacuum. Then the temperature is raised to about 0 0 C, and then to about 10 0 C.
- the product can further be dried at a temperature of about 15°C or above.
- Deionised water (3.5 L) was cooled at a temperature of 5° to 10 0 C.
- Sodium bicarbonate 250 g was added slowly to the deionised water at a temperature of 5° to 10 0 C and stirred until complete dissolution of the solid.
- the solution was filtered using 0.45 micron filter and transferred to lyophilizer trays, pre-cooled to 0° to -5°C, to form a layer of 8 to 10 millimeter thickness.
- the solution was frozen to -40 0 C and held at the same temperature for 180 minutes, followed by the application of vacuum (150 mTorr). The temperature was raised to 0 0 C in 300 minutes and held at the same temperature for 600 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a process for the preparation of crystalline lyophilized sodium bicarbonate.
Description
A PROCESS FOR THE PREPARATION OF LYOPHILIZED SODIUM
BICARBONATE
Field of the Invention The present invention provides a process for the preparation of crystalline lyophilized sodium bicarbonate.
Background of the Invention
Sodium bicarbonate is used as an inactive ingredient in injectable pharmaceutical preparations such as ertapenem, octreotide acetate, fomivirsen sodium, mannitol, and poractant alfa and in oral tablets such as ESTRATEST® (Esterified Estrogens and Methyltestosterone) and terfenadine. Sterile water for injection containing sodium bicarbonate is used for reconstituting certain drugs such as ceftizoxime, cefazolin, cimetidine hydrochloride, cefoxitin sodium and ceftriaxone sodium. Sodium bicarbonate is also used in the preparation of sodium salts of the drugs such as cilastatin and cefotetan. Sodium bicarbonate is also an ingredient in oral solutions for gastrointestinal lavage such as COLYTE®. It is also used for pH neutralization of drugs such as metronidazole and ascorbic acid prior to parenteral administration.
Sodium bicarbonate of higher purity is commercially produced by injecting gaseous carbon dioxide into a sodium carbonate solution of such composition that results in crystallization of sodium bicarbonate as the solution becomes fully saturated with carbon dioxide. The crystals are separated by centrifuging and filtering, and then dried to remove the traces of moisture.
As detailed in PCT Patent Publication No. WO 94/14705, sodium bicarbonate wet cake is traditionally dried by using conventional rotary steam tube dryers. Such methods involve high temperature dehydration and steam pressure up to thirty five atmosphere. The dried material usually has high bulk density and the crystals resulting from this process usually have irregular particle size distribution and dendritic structures, which are
physically weak and readily disintegrate into finer fragments on handling. Further, at higher temperatures, sodium bicarbonate tends to be converted into sodium carbonate.
U.S. Patent No 3,647,365 describes a method to obtain hollow beads of sodium bicarbonate having bulk density of 25 - 32 pounds per cubic foot, and the process involves drying of the product by warming under carbon dioxide environment. Such methods of drying by warming consume considerable time for complete removal of the moisture. U.S. Patent No. 5,290,322 provides a method to prepare sodium bicarbonate crystals having regular particle size distribution by mobile bed crystallization method. However, the method needs to be carried out at a temperature of about 700C under carbon dioxide environment and results in a mean particle size of about 900 microns.
Summary of the Invention
The present inventors have now surprisingly found that crystalline sodium bicarbonate with high purity; optimum bulk density and uniform particle size distribution can be prepared in comparatively a shorter reaction time by lyophilizing a solution of sodium bicarbonate. The method does not require carbon dioxide atmosphere, high pressure or temperature conditions, and yet results in a pure product with moisture content less than about 0.25 % w/w. The present method is suitable for industrial preparation of pharmaceutical grade crystalline sodium bicarbonate.
Detailed Description of the Invention
A first aspect of the present invention provides a crystalline lyophilized sodium bicarbonate. The crystalline lyophilized sodium bicarbonate of the present invention has bulk density ranging from about 0.10 to about 0.25 g/ml and tapped density ranging from 0.30 to about 0.40 g/ml.
A second aspect of the invention provides crystalline lyophilized sodium bicarbonate having particle size wherein 90% of the particles (do 9) have particle diameter 40 microns or less.
A third aspect of the present invention provides a process for the preparation of crystalline sodium bicarbonate, wherein the process comprises a) lyophilizing the solution of sodium bicarbonate in lyophilizer having tray thickness of about 15 mm or less, and b) isolating crystalline sodium bicarbonate from the reaction mass thereof.
Sodium bicarbonate of any morphology or particle size range prepared by any of the prior art methods can be used as a starting substrate. The sodium bicarbonate is dissolved in water at a temperature of about 5° to about 15°C. The solution is optionally filtered through a micron filter and transferred to lyophilizer trays having the temperature of about 0° to about -100C. The thickness of the solution layer on the lyophilizer trays is less than about 15 millimeter. The solution is cooled to a temperature of -200C or less under vacuum. Then the temperature is raised to about 00C, and then to about 100C. The product can further be dried at a temperature of about 15°C or above.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.
Example 1: Preparation of Crystalline Lyophilized Sodium Bicarbonate:
Deionised water (3.5 L) was cooled at a temperature of 5° to 100C. Sodium bicarbonate (250 g) was added slowly to the deionised water at a temperature of 5° to 100C and stirred until complete dissolution of the solid. The solution was filtered using 0.45 micron filter and transferred to lyophilizer trays, pre-cooled to 0° to -5°C, to form a layer of 8 to 10 millimeter thickness. The solution was frozen to -400C and held at the same temperature for 180 minutes, followed by the application of vacuum (150 mTorr). The temperature was raised to 00C in 300 minutes and held at the same temperature for 600 minutes. The temperature was further raised to 100C in 120 minutes and held at the same temperature for 600 minutes. The temperature of the reaction mixture so obtained was raised to 15°C in 60 minutes and held at the same temperature for 360 minutes. The temperature was further raised to 25°C in 120 minutes and held at the same temperature for 300 minutes, followed by the release of vacuum to obtain the title compound.
Yield: 225 g
Purity: 99.6 % w/w
Loss on Drying: 0.08%
Bulk Density: 0.24 g/ml
Tapped Bulk Density: 0.34 g/ml
Particle Size (measured by Malvern Mastersizer):
D (0.1) D (0.5) D (0.9)
3μ 15μ 37μ
Claims
WE CLAIM: 1. A crystalline lyophilized sodium bicarbonate. 2. A crystalline lyophilized sodium bicarbonate having a bulk density ranging from about 0.10 to about 0.25 g/ml. 3. A crystalline lyophilized sodium bicarbonate having a tapped density ranging from about 0.30 to about 0.40 g/ml. 4. A crystalline lyophilized sodium bicarbonate having particle size wherein 90% of the particles (do 9) have particle diameter of 40 microns or less. 5. A process for the preparation of crystalline lyophilized sodium bicarbonate, wherein the process comprises, a) lyophilizing the solution of sodium bicarbonate in lyophilizer having tray thickness of about 15 mm or less, and b) isolating crystalline sodium bicarbonate from the reaction mass thereof. 6. A process as claimed in claim 5, wherein the solution of sodium bicarbonate is obtained by dissolving sodium bicarbonate in water. 7. A process as claimed in claim 6, wherein sodium bicarbonate is dissolved at a temperature of about 15°C or less. 8. A process as claimed in claim 5, wherein step a) is carried out at a temperature of about -200C or less. 9. A process as claimed in claim 5, wherein the reaction mixture is filtered before lyophilizing. 10. A process as claimed in claim 5, wherein step a) is carried out under vacuum.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2364/DEL/2005 | 2005-09-05 | ||
IN2364DE2005 | 2005-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007029159A1 true WO2007029159A1 (en) | 2007-03-15 |
Family
ID=37564334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/053085 WO2007029159A1 (en) | 2005-09-05 | 2006-09-01 | A process for the preparation of lyophilized sodium bicarbonate |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101282908A (en) |
WO (1) | WO2007029159A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760998A4 (en) * | 2011-11-22 | 2015-05-13 | Siemens Healthcare Diagnostics | Devices containing dried reagents for reconstitution as calibration and/or quality control solutions, and methods of production and use thereof |
RU2670956C2 (en) * | 2012-12-03 | 2018-10-26 | Омрикс Биофармасьютикалс Лтд. | Thrombin solution and methods for use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114920269B (en) * | 2022-06-28 | 2022-11-08 | 浙江天瑞药业有限公司 | Preparation method of sodium bicarbonate for injection |
CN116282080B (en) * | 2023-04-07 | 2024-05-03 | 赣州赛可韦尔科技有限公司 | Continuous freezing production process of sodium sulfate in waste lithium iron phosphate battery recovery process |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4485086A (en) * | 1983-04-11 | 1984-11-27 | Wong Dennis W | Radiolabeled tumor imaging agent and method of preparation |
WO1992002455A1 (en) * | 1990-08-06 | 1992-02-20 | Bicarbon Industrial E Comercial | Process for obtaining of sodium and potassium bicarbonates by dry route |
US5130305A (en) * | 1988-11-14 | 1992-07-14 | Erbamont, Inc. | Cyclophosphamide - sodium bicarbonate lyophilizates |
US5411750A (en) * | 1993-04-27 | 1995-05-02 | Church & Dwight Co., Inc. | Ultrafine sodium bicarbonate powder |
-
2006
- 2006-09-01 CN CNA2006800378729A patent/CN101282908A/en active Pending
- 2006-09-01 WO PCT/IB2006/053085 patent/WO2007029159A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4485086A (en) * | 1983-04-11 | 1984-11-27 | Wong Dennis W | Radiolabeled tumor imaging agent and method of preparation |
US5130305A (en) * | 1988-11-14 | 1992-07-14 | Erbamont, Inc. | Cyclophosphamide - sodium bicarbonate lyophilizates |
WO1992002455A1 (en) * | 1990-08-06 | 1992-02-20 | Bicarbon Industrial E Comercial | Process for obtaining of sodium and potassium bicarbonates by dry route |
US5411750A (en) * | 1993-04-27 | 1995-05-02 | Church & Dwight Co., Inc. | Ultrafine sodium bicarbonate powder |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760998A4 (en) * | 2011-11-22 | 2015-05-13 | Siemens Healthcare Diagnostics | Devices containing dried reagents for reconstitution as calibration and/or quality control solutions, and methods of production and use thereof |
US9244085B2 (en) | 2011-11-22 | 2016-01-26 | Siemens Healthcare Diagnostics Inc. | Devices containing dried reagents for reconstitution as calibration and/or quality control solutions, and methods of production and use thereof |
RU2670956C2 (en) * | 2012-12-03 | 2018-10-26 | Омрикс Биофармасьютикалс Лтд. | Thrombin solution and methods for use thereof |
RU2670956C9 (en) * | 2012-12-03 | 2018-11-21 | Омрикс Биофармасьютикалс Лтд. | Thrombin solution and methods for use thereof |
US10479987B2 (en) | 2012-12-03 | 2019-11-19 | Omrix Biopharmaceuticals Ltd. | Thrombin solution and methods of use thereof |
US11225652B2 (en) | 2012-12-03 | 2022-01-18 | Omrix Biopharmaceuticals Ltd. | Thrombin solution and methods of use thereof |
US11993797B2 (en) | 2012-12-03 | 2024-05-28 | Omrix Biopharmaceuticals Ltd. | Thrombin solution and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101282908A (en) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100484525C (en) | Pantoprazole sodium freeze-dried powder injection and preparing method thereof | |
JP2004532277A5 (en) | ||
WO2014195966A2 (en) | Amorphous form of canagliflozin and process for preparing thereof | |
WO2007029159A1 (en) | A process for the preparation of lyophilized sodium bicarbonate | |
KR100647951B1 (en) | Purification and crystallization process for riboflavin | |
MX2013001251A (en) | Highly crystalline valsartan. | |
CN101618012B (en) | Insoluble medicine solid dispersoid and preparation method thereof | |
CN105055342A (en) | Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer | |
JP4965013B2 (en) | Method for producing spray granules containing riboflavin | |
CA2319514A1 (en) | Spray drying of pharmaceutical formulations containing amino acid-based materials | |
EP2503990B1 (en) | Process for the preparation of gadobenate dimeglumine complex in a solid form | |
CN101912370B (en) | D(-)-sulbenicillin disodium powder for injection and preparation process thereof | |
CN108727448B (en) | Spiromycin antibiotic spherical crystal and preparation method thereof | |
US20060263424A1 (en) | Pharmaceutical compositions comprising clavulanic acid | |
Rams-Baron et al. | Amorphous drug preparation methods | |
CN111454255A (en) | Preparation method of small-particle-size azilsartan | |
JP2004059585A (en) | Stable amorphous calcium pseudomonate and preparative method for the same | |
US20040007689A1 (en) | Process for controlling the hydrate mix of a compound | |
EP1534721B1 (en) | Process for controlling the hydrate mix of the disodium salt of fosfluconazole | |
JP3931884B2 (en) | Tablet manufacturing method | |
CN104306341A (en) | Lansoprazole special superfine powder freeze-dried preparation and preparing method thereof | |
CN104910136B (en) | A kind of compound of pantoprazole sodium and preparation thereof adopting particle process crystal product molecule to assemble to prepare with form optimisation technique | |
CN112573547A (en) | Preparation method of nano lithium carbonate | |
JP2022542866A (en) | Process for obtaining amorphous remimazolam besilate | |
CN116589483A (en) | Preparation method of high-purity flomoxef sodium for injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680037872.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2841/DELNP/2008 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06795888 Country of ref document: EP Kind code of ref document: A1 |